kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human TNF-alpha (HPLC-verified), 100µg  

Recombinant Human TNF-alpha (HPLC-verified), 100µg

Recombinant Human TNF-alpha, Val 77 - Leu 233, produced in human 293 cells (HEK293), premium grade

Synonyms: TNF, DIF, TNF-alpha, TNFalpha, TNFA, TNFSF2, TNF-A, cachexin, cachectin, TNF-a, TNFa, tumor-necrosis-factor-alpha, TNFa cytokine, TNF alpha protein, ADC target

More details


Availability: within 7 days

247,00 €

Tumor necrosis factor alpha (TNFα) is a cytokine produced primarily by monocytes and macrophages.
It is found in synovial cells and macrophages in the tissues.The primary role of TNFα is in the regulation of immune cells. TNFα is able to induce apoptotic cell death, to induce inflammation, and to inhibit tumorigenesis and viral replication. Dysregulation of TNFα production has been implicated in a variety of human diseases, including major depression, Alzheimer's disease and cancer. Recombinant TNFα is used as an immunostimulant under the INN tasonermin. TNFα can be produced ectopically in the setting of malignancy and parallels parathyroid hormone both in causing secondary hypercalcemia and in the cancers with which excessive production is associated.

Recombinant Human TNF-alpha, premium grade(TNA-H4211) is expressed from human 293 cells (HEK293). It contains AA Val 77 - Leu 233 (Accession # P01375-1).
Predicted N-terminus: Val 77
It is produced under our rigorous quality control system that incorporates a comprehensive set of tests including sterility and endotoxin tests. Product performance is carefully validated and tested for compatibility for cell culture use or any other applications in the early preclinical stage. When ready to transition into later clinical phases, we also offer a custom GMP protein service that tailors to your needs. We will work with you to customize and develop a GMP-grade product in accordance with your requests that also meets the requirements for raw and ancillary materials use in cell manufacturing of cell-based therapies.

Molecular Characterization
This protein carries no "tag".
The protein has a calculated MW of 17.4 kDa. The protein migrates as 17 kDa under reducing (R) condition (SDS-PAGE).

Less than 0.02 EU per μg by the LAL method.

The sterility testing was performed by membrane filtration method.


>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 24 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Please refer to product data sheet.

Clinical and Translational Updates

(1) "High-voltage pulsed radiofrequency improves ultrastructure of DRG and enhances spinal microglial autophagy to ameliorate neuropathic pain induced by SNI"
Chen, Xu, Yu et al
Sci Rep (2024) 14 (1), 4497
(2) "JianPiYiShen formula prevents cisplatin-induced acute kidney injury in mice by improving necroptosis through MAPK pathway"
Li, He, Liu et al
BMC Complement Med Ther (2024) 24 (1), 101
(3) "Anti-psoriatic characteristics of ROCEN (topical Arthrocen) in comparison with Cyclosporine A in a murine model"
Goudarzi, Min-Ho Kim, Partoazar
BMC Complement Med Ther (2024) 24 (1), 100
Showing 1-3 of 264712 papers.